ATC Group: N06BC01 Caffeine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N06BC01 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N06 Psychoanaleptics
3 N06B Psychostimulants, agents used for ADHD and nootropics
4 N06BC Xanthine derivatives
5 N06BC01 Caffeine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.4 g
PAREN - Parenteral 0.4 g

Active ingredients in N06BC01

Active Ingredient Description
Caffeine

Caffeine is structurally related to the methylxanthines theophylline and theobromine. Caffeine’s main action is as a CNS stimulant.

Related product monographs

Title Information Source Document Type  
Caffeine Citrate 10mg/ml Inj. Sol. Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
GENCEBOK Solution for infusion European Medicines Agency (EU) MPI, EU: SmPC
PEYONA Solution European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Brazil (BR)

Canada (CA)

Croatia (HR)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Italy (IT)

Japan (JP)

Lithuania (LT)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Romania (RO)

South Africa (ZA)

Spain (ES)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.